- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
Results
74
A Penny Stocks screener, typically smaller or younger companies trading at a price below 5, with a focus on solid financial health that should present companies with a lower risk profile than other early-stage businesses
74 companies
Puma Biotechnology
Market Cap: US$237.2m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$4.72
7D
8.8%
1Y
85.1%
Xenetic Biosciences
Market Cap: US$5.0m
A biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
XBIO
US$3.25
7D
-0.6%
1Y
-18.1%
Protalix BioTherapeutics
Market Cap: US$156.3m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.06
7D
10.2%
1Y
89.0%
Lipocine
Market Cap: US$15.0m
A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
LPCN
US$2.76
7D
-3.2%
1Y
-41.8%
Acrivon Therapeutics
Market Cap: US$49.7m
A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
ACRV
US$1.56
7D
0%
1Y
-78.2%
AC Immune
Market Cap: US$249.3m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.73
7D
11.0%
1Y
-26.0%
Adagene
Market Cap: US$96.6m
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
ADAG
US$2.03
7D
-0.5%
1Y
-7.7%
Nautilus Biotechnology
Market Cap: US$91.6m
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
NAUT
US$0.72
7D
-0.07%
1Y
-74.5%
Allogene Therapeutics
Market Cap: US$259.6m
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
ALLO
US$1.23
7D
8.8%
1Y
-53.1%
ProKidney
Market Cap: US$806.3m
A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
PROK
US$2.72
7D
7.5%
1Y
32.0%
Vanda Pharmaceuticals
Market Cap: US$281.3m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.90
7D
11.6%
1Y
1.0%
Aprea Therapeutics
Market Cap: US$8.4m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$1.42
7D
-5.3%
1Y
-50.5%
Alector
Market Cap: US$321.9m
A late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases.
ALEC
US$3.16
7D
7.1%
1Y
-35.9%
PMV Pharmaceuticals
Market Cap: US$73.1m
A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
PMVP
US$1.47
7D
17.6%
1Y
-1.3%
Artiva Biotherapeutics
Market Cap: US$63.3m
A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
ARTV
US$2.88
7D
26.3%
1Y
-80.9%
ESSA Pharma
Market Cap: US$9.8m
A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
EPIX
US$0.20
7D
-0.9%
1Y
-96.7%
Connect Biopharma Holdings
Market Cap: US$90.3m
A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.
CNTB
US$1.72
7D
6.8%
1Y
34.4%
Werewolf Therapeutics
Market Cap: US$81.9m
A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.
HOWL
US$2.08
7D
48.2%
1Y
3.8%
Relay Therapeutics
Market Cap: US$767.2m
Operates as a clinical-stage precision medicines company.
RLAY
US$4.52
7D
10.5%
1Y
-36.0%
Mereo BioPharma Group
Market Cap: US$286.4m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$1.80
7D
4.0%
1Y
-55.0%
PharmaCyte Biotech
Market Cap: US$7.3m
A biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States.
PMCB
US$1.07
7D
10.2%
1Y
-40.6%
Black Diamond Therapeutics
Market Cap: US$180.5m
A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
BDTX
US$3.26
7D
3.2%
1Y
-22.4%
MediciNova
Market Cap: US$62.3m
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
MNOV
US$1.25
7D
2.5%
1Y
-38.1%
Organogenesis Holdings
Market Cap: US$603.8m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$4.90
7D
6.1%
1Y
76.9%
C4 Therapeutics
Market Cap: US$184.3m
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
CCCC
US$2.42
7D
-28.4%
1Y
-61.3%
Genelux
Market Cap: US$162.1m
A clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
GNLX
US$4.37
7D
11.8%
1Y
120.7%
Neumora Therapeutics
Market Cap: US$309.3m
A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
NMRA
US$1.83
7D
26.2%
1Y
-85.7%
Rallybio
Market Cap: US$24.5m
A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
RLYB
US$0.59
7D
3.9%
1Y
-46.3%
Coherus Oncology
Market Cap: US$181.3m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.58
7D
17.0%
1Y
59.5%
Zura Bio
Market Cap: US$133.9m
A clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.
ZURA
US$2.29
7D
20.5%
1Y
-41.4%
Erasca
Market Cap: US$502.1m
A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
ERAS
US$1.91
7D
14.4%
1Y
-30.3%
Metagenomi
Market Cap: US$81.8m
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
MGX
US$2.09
7D
11.2%
1Y
0%
Cumberland Pharmaceuticals
Market Cap: US$44.6m
A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
CPIX
US$3.06
7D
-5.3%
1Y
146.8%
Pliant Therapeutics
Market Cap: US$89.6m
A biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
PLRX
US$1.46
7D
0%
1Y
-87.1%
Lisata Therapeutics
Market Cap: US$20.1m
A clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
LSTA
US$2.35
7D
3.1%
1Y
-17.8%
Relmada Therapeutics
Market Cap: US$55.4m
Operates as a clinical-stage biotechnology company in the United States.
RLMD
US$1.65
7D
9.3%
1Y
-51.2%